|
gptkbp:instanceOf
|
gptkb:drug
gptkb:angiotensin_II_receptor_blocker
|
|
gptkbp:approvalYear
|
1995
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
C09CA01
|
|
gptkbp:bioavailability
|
33%
|
|
gptkbp:brand
|
gptkb:Cozaar
|
|
gptkbp:CASNumber
|
114798-26-4
|
|
gptkbp:category
|
gptkb:imidazole_derivative
gptkb:sartan
gptkb:antihypertensive_agent
biphenyl compound
tetrazole
chlorobenzene derivative
|
|
gptkbp:chemicalFormula
|
C22H23ClN6O
|
|
gptkbp:contraindication
|
pregnancy
severe hepatic impairment
|
|
gptkbp:cost
|
low
|
|
gptkbp:developedBy
|
gptkb:Merck_&_Co.
|
|
gptkbp:discoveredIn
|
1986
|
|
gptkbp:eliminationHalfLife
|
2 hours
|
|
gptkbp:excretion
|
urine
bile
|
|
gptkbp:firstBook
|
gptkb:angiotensin_II_receptor_blocker
|
|
gptkbp:genericAvailable
|
yes
|
|
gptkbp:interactsWith
|
gptkb:NSAIDs
lithium
diuretics
potassium supplements
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
gptkb:angiotensin_II_receptor_antagonist
|
|
gptkbp:metabolism
|
liver
EXP3174
|
|
gptkbp:pregnancyCategory
|
gptkb:D_(Australia)
D (US)
|
|
gptkbp:proteinBinding
|
98%
|
|
gptkbp:PubChem_CID
|
3961
DB00678
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
dizziness
fatigue
cough
hyperkalemia
|
|
gptkbp:UNII
|
JMS50MPO89
|
|
gptkbp:usedFor
|
heart failure
hypertension
diabetic nephropathy
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
included
|
|
gptkbp:bfsParent
|
gptkb:CYP3A4
gptkb:Cozaar
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
losartan
|